To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptoms
Phase of Trial: Phase IV
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Iguratimod (Primary)
- Indications Autoimmune disorders
- Focus Therapeutic Use
- 10 Apr 2018 Planned End Date changed from 1 May 2018 to 1 Jun 2018.
- 10 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
- 15 Jan 2018 New trial record